The shares of Tyme Technologies Inc. (TYME) have gained 0.82% at $1.23 at last check during pre-hours trading today. A -9.63% fall was recorded in TYME stock last trading session to $1.22. Trading volume of TYME stock was 6.88 million shares, which is below its average daily trading volume of 9.23 million shares during the past 50 days.
TYME stock has lost 9.91% in the last five days; however, in the last month, it has lost -7.58%. Over the last three months, the company price has dropped -23.27%, and this year it has gained 0.83 percent. After losing ground in the last session, the company remained falling in premarket trades today.
TYME’s latest developments:
TYME is an emerging biotech company focused on cancer metabolism-based therapies (CMBTs) that have the potential to be effective in treating different tumor types while being relatively safe. Instead of regulating specific mutations within a tumor, TYME’s therapeutic approach targets the innate metabolic weaknesses of cancer cells in order to expose them to oxidative stress and drive them towards cell death through exposure to the body’s natural immune system.
A significant amount of the company’s resources are being devoted to its new compound, SM-88. A TYME study demonstrated that SM-88 showed promising clinical results in multiple advanced cancers, including pancreatic, prostate, sarcomas, and breast. This supports TYME’s emerging CMBT pipeline.
The United States Patent and Trademark Office has granted additional patents to the company related to its metabolomic technology platform, announced the company this week.
In the US patent 11,058,638, the TYME patent proposes a way to deliver therapeutics directly to cancer cells. By combining the tyrosine isomer racemetyrosine with a second therapeutic agent, the company has developed fusion compounds that may be capable of providing targeted delivery to cancer cells from the outside.
In this method of delivery, non-essential amino acids, such as tyrosine, are consumed by cancer cells from their surroundings to support their growth since they cannot produce them on their own. The company could expand its current cancer-metabolism-based strategy with this technology which could deliver toxic therapies in an efficiently targeted manner that could be useful for a range of anticancer drugs with improved safety and efficacy.
Company further plans:
TYME also demonstrates an innovative spirit through its delivery technology. Although this approach is still in its infancy, if it proves successful, it can be a widely utilized platform technology. TYME’s delivery technology is a preclinical research method of drug delivery focused on research studies in the U.S. for no specific disease indication and needs further testing, which will begin this year.
